Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA

摘要

IntroductionBasal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic medical records (EMR) data from the IBM? Explorys database to evaluate the probability of achieving glycemic control over 24?months after BI initiation in patients with T2D in the USA. MethodsA cohort of 6597 patients with T2D who started BI following OAD(s) and had at least one valid glycated hemoglobin (HbA1c) result recorded both within 90?days before and 720?days after BI initiation were selected. We estimated the changes from baseline in HbA1c every 6?months, the quarterly conditional probabilities of reaching HbA1c? ResultsOur cohort was representative of patients with T2D who initiated BI from OADs in the USA. The average HbA1c was 9.1% at BI initiation, and decreased robustly (1.5%) in the first 6?months after initiation with no further reductions thereafter. The conditional probability of reaching glycemic control decreased rapidly in the first year (26.6% in Q2; 17.6% in Q3; 8.6% in Q4), and then remained low (≤?6.1%) for each quarter in the second year. Cumulatively, about 38% of patients reached HbA1c? ConclusionOur study of real-world data from a large US EMR database suggested that among patients with T2D who initiated BI after OADs, the likelihood of reaching glycemic control diminished over time, and remained low from 12?months onwards. Additional treatment options should be considered if patients do not reach glycemic control within 12?months of BI initiation. FundingSanofi Corporation.